Biology of post-transplant relapse: actionable features

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Relapse of acute myeloid leukemia (AML) post-allogeneic hematopoietic cell transplantation (HCT) remains a significant challenge, contributing to high mortality rates.
• Advances in omic technologies provide a dynamic evolutionary perspective on cancer and host changes during HCT treatments.

Purpose of the Study:

• To review current knowledge on the molecular characteristics of relapsing AML.
• To focus on alterations in the mutational landscape and tumor-immune system interactions.
• To explore the clinical translation of these findings for patient monitoring and relapse management.

Main Methods:

• Literature review of studies investigating molecular changes in relapsing AML after HCT.
• Analysis of data on mutational evolution and immune system interplay.
• Synthesis of information for clinical application.

Main Results:

• Relapsing AML exhibits dynamic changes in its mutational profile.
• The interaction between the tumor and the donor immune system is crucial in relapse dynamics.
• Omic data provides insights into relapse mechanisms.

Conclusions:

• Understanding molecular relapse features is key to improving outcomes in AML patients undergoing HCT.
• Translating molecular insights can guide personalized monitoring and therapeutic strategies to prevent and treat relapse.
• Further research into tumor evolution and immune interactions is warranted.